| 摘要 |
<p>Pharmaceutical compositions in the form of a solution comprising (a) ritonavir or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically acceptable organic solvent which comprises a long chain fatty acid which is a saturated, mono- or di-unsaturated C12-C18 carboxylic acid or mono-unsaturated C16-C20 carboxylic acid which is liquid at room temperature, preferably oleic acid, in the amount of from 30 % to 75 % by weight of the total solution; and (c) water in the amount of from 0,4 % to 3,5 % by weight of the total solution. Preferred pharmaceutical compositions comprise in addition to ritonavir another HIV protease inhibiting compound, and, as an auxiliary substance, a pharmaceutically acceptable surfactant.</p> |
